On-Demand Programs
A Snapshot into the Management of GEA and BTC: The Role of Nurses and Advanced Practice Providers
The enduring activity is designed to enhance the target healthcare professionals' (HCPs) proficiency in applying current guidelines for HER2 testing in patients with gastroesophageal adenocarcinoma (GEA) and biliary tract cancer (BTC). By exploring the efficacy of HER2-targeted therapies for HER2-positive GEA and BTC, the activity seeks to equip HCP’s with the knowledge to develop effective treatment plans and provide robust support for patients experiencing adverse events associated with these therapies.
RELEASED DATE: August 08, 2025
EXPIRATION DATE: August 08, 2026
Managing HER2—Positive Biliary Tract Cancers and Gastroesophageal Adenocarcinoma through Novel and Emerging Approaches in Practice
RELEASED DATE: March 07, 2025
EXPIRATION DATE: March 07, 2026
Understanding HER2: Updates on New and Emerging Treatment Approaches for Gastroesophageal Adenocarcinoma and Biliary Tract Cancer
This enduring activity will explore the best-practice strategies for the use of molecular testing to determine HER2 expression levels in patients with GEA and BTC, applying current guidelines for the management of HER2-positive GEA and BTC to daily clinical practice, including evaluating the latest clinical data for HER2-targeted therapies in patients with HER2-positive GEA or BTC. Strategies for effective and proactivity managing the AEs associated with HER2-targeted therapy in patients with GEA or BTC will also be explored.
RELEASED DATE: June 23, 2025
EXPIRATION DATE: June 23, 2026
